Rubella vaccine introduction Laos 9

in page functions
Rubella 9

Workers prepare to test blood samples from people with fever and rash – the markets for both measles and rubella – at the Laos National Center for Laboratory and Epidemiology in Laos' capital Vientiane, November 2011. The Laos Ministry of Health is working to improve surveillance for rubella so that cases can be laboratory confirmed. The blood samples are sent from the field for testing.

CREDIT: The Measles Initiative/C. McNab/2011

Download high-res version

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here